Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tazemetostat
Drug ID BADD_D02598
Description Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.[L11476] Tazemetostat was first named in literature as EPZ-6438.[A190363] Tazemetaostat was granted FDA approval on 23 January 2020.[L11476]
Indications and Usage Tazemetostat is indicated to treat adult and pediatric patients 16 years and older with metastatic or locally advanced epithelioid sarcoma that is not eligible for complete resection.[L11476]
Marketing Status approved; investigational
ATC Code L01XX72
DrugBank ID DB12887
KEGG ID D11444
MeSH ID C000593333
PubChem ID 66558664
TTD Drug ID D00EQL
NDC Product Code 72607-100
UNII Q40W93WPE1
Synonyms tazemetostat | N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide | EPZ-6438 monohydrochloride | tazemetostat dihydrobromide | (1,1'-biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:2) | tazemetostat hydrochloride | (1,1'-biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-, hydrochloride (1:1) | tazemetostat monohydrochloride | tazemetostat hydrobromide | N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide monohydrobromide | tazemetostat monohydrobromide | EPZ-6438 monohydrobromide | EPZ-6438 trihydrochloride | EZ-438 | EZ438 | EPZ-6438 dihydrobromide | E 7438 | E7438 | E-7438 hydrobromide | Tazverik | EPZ-6438 | tazemetostat trihydrochloride
Chemical Information
Molecular Formula C34H44N4O4
CAS Registry Number 1403254-99-8
SMILES CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.0010.000381%
Alopecia23.02.02.0010.000761%
Asthenia08.01.01.0010.000246%Not Available
Diarrhoea07.02.01.0010.000571%
Fatigue08.01.01.0020.001768%
Headache17.14.01.0010.000571%
Nausea07.01.07.0010.001142%
Pyrexia08.05.02.0030.000437%
Thrombocytopenia01.08.01.0020.000381%Not Available
Malignant neoplasm progression16.16.01.0050.000112%Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.000627%
Disease progression08.01.03.0380.001858%
Drug intolerance08.06.01.0130.000571%Not Available
Cytopenia01.03.03.0120.000761%Not Available
Taste disorder17.02.07.029; 07.14.03.0040.001142%Not Available
The 1th Page    1    Total 1 Pages